All posts in: Uncategorized

Imbed Biosciences’ Team Members Honored in List of Health Innovators

Madison, WI, November 7, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, is pleased to share that two of its team members—Jeffrey Dalsin, Ph.D. and Robert Beckman—have been named to the 2017 edition of Madison Magazine’s prestigious M-List.  This year, the M-List honors health innovators.  Dr. Dalsin serves as Imbed’s Vice President of Product Development, while Mr. Beckman serves as an outside director on the company’s Board of Directors.

Dr. Dalsin has spent his professional career developing medical technology and serving in leadership roles in start-up companies in Madison.  Prior to joining Imbed a little over a year ago, Jeff previously helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development.  In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011.   Most recently, he led a start-up ultrasound technology company. “I am honored and humbled to be included with such an esteemed group.  I look forward to continuing to help make Madison a leader in health technology,” Dalsin said.

Mr. Beckman, in addition to begin a company director, is currently President and CEO of Wicab Inc, a medical device company developing an assistive device for visually impaired. The device translates digital information from a video camera into gentle electrical stimulation patterns on the surface of the tongue. After a pivotal clinical study, Wicab recently obtained regulatory approvals for marketing the device in the U.S. and Western Europe.  Mr. Beckman was vice president and chief financial officer of Lunar Corp., Madison, WI, and later, of Bone Care International, Middleton, WI. Lunar Corp made machines to screen for bone density, and was acquired by GE Medical in 2000. Bone Care developed drugs to treat a condition that can lead to bone damage in kidney patients, and was bought by Genzyme in 2005.

“Imbed is proud to have two leaders in health innovation among its very talented team.  Both Jeff and Bob bring great experience to our effort, and will be key in ensuring Imbed’s success as the company continues to bring MircoLyte Ag, our FDA-cleared antimicrobial wound dressing, and other innovative products to market,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

 

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Imbed Biosciences Advanced Wound Care Portfolio Highlighted SAWC Spring 2017

Madison, WI, April 4, 2017 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company will present new data and information featuring its MicroLyte™ antimicrobial and antibiofilm wound dressings at the Spring Symposium on Advanced Wound Care (SAWC) in San Diego, CA from April 5-8, 2017. The company will also have a presence in the exhibitor space at booth #1110. SAWC is the nation’s largest interdisciplinary wound care forum.

The company’s poster presentations will highlight research conducted by multi-disciplinary teams internal to Imbed Biosciences, as well as at the University of Wisconsin-Madison, the University of California-Davis, and Mission Hospital (Asheville, NC) including recent clinical outcomes using the company’s breakthrough MicroLyte™ Ag antimicrobial wound dressing on complex chronic wounds. The study is ongoing and involves 100 patients at Mission Hospital with a variety of complex chronic wounds. Imbed will also present veterinary case study outcomes as well as development of a dressing which can reliably eradicate an established biofilm in a wound bed and thus be used in an infected wound.

“The work that will be presented at SAWC represents a wide range of our current research and commercial activities. Meeting attendees will see clinical outcomes in both human and veterinary patients along with results from our early development work on a next generation antibiofilm product,” said Ankit Agarwal, President and CEO of Imbed Biosciences.

Additionally, prospective users will get a first-look at Imbed’s groundbreaking, FDA-cleared MicroLyte™ Ag ultrathin, antimicrobial wound dressing. MicroLyte™ Ag has only a fraction of the silver of competitive dressings, leading to lower incidences of tissue staining and toxicity while still maintaining high antimicrobial activity. FDA cleared MicroLyte™ Ag for use for up to three days in acute wounds such as, lacerations, skin tears, abrasions, surgical wounds (donor and graft sites, incisions), partial thickness first and second degree burns, and partial to full-thickness dermal ulcers such as, diabetic, decubitus, venous stasis, arterial stasis ulcers.

Poster presentations of interest include:

Ultrathin Hydrogel Dressings Containing Gallium Ions and Silver Nanoparticles for the Elimination of Biofilms
G. Pranami1, T. B. Nelson1, E. C. Crawford1, J. L. Dalsin1, M. H. Herron2, C. J. Czuprunski3, N. L. Abbott2, A. Agarwal1,2
1Imbed Biosciences Inc., Madison, WI, USA; 2Department of Chemical Engineering, University of Wisconsin-Madison; 3School Of Veterinary Medicine, University of Wisconsin-Madison

Use of an antimicrobial microfilm wound dressing in spontaneous wounds in animals
Jonathan F. McAnulty, DVM, PhD1 and Michael J. Schurr, MD2
1Department of Surgical Sciences, University of Wisconsin – Madison, WI; 2Mission Hospital, Asheville, NC

Ultrathin Dissolvable Antimicrobial Wound Dressing Is Safe and Effective In Patients With Complex Chronic Wounds
David Humphrey, MD1, Michael J. Schurr, MD2, William Shillinglaw MD1
1Mission Hospital, Asheville NC; 2MAHEC Department of Surgery, Asheville, NC

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

Imbed Bio Recruits Jeffrey Dalsin To Lead Product Development

IMBED BIO RECRUITS JEFFREY DALSIN TO LEAD PRODUCT DEVELOPMENT

Madison, WI, October 1, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that Jeffrey Dalsin, Ph.D. will join the Imbed leadership team as Vice President of Product Development. Dr. Dalsin will lead development of Imbed’s flagship product Microlyte® Ag wound dressings and product pipeline under quality control for new medical applications.  He brings more than 15 years’ experience developing novel biomaterials and medical devices.  Based on his doctoral work, Jeff helped cofound Nerites Corporation, a start-up that commercialized an innovative surgical adhesive and served as Director of Product Development.  In that role, Jeff wore many hats and gained broad start-up operational experience through the company’s successful acquisition in 2011.   Most recently, he led a start-up ultrasound technology company.  Jeff earned a B.S. in Life Sciences from the University of Illinois at Urbana-Champaign and M.S. and Ph.D. degrees from Northwestern University.

“Jeff served as a consultant to Imbed in the company’s early days on SBIR grants and quality management system. He is an excellent scientist and brings rigor of managing product development in start-up environment.  I am happy to welcome him back in a more formal role,” said Ankit Agarwal, Imbed’s President and CEO.

“I’ve known Ankit for several years now and have followed Imbed’s progress with great interest.  I am very happy to have the opportunity to again contribute to this team and assist in bringing a much-need wound care device to clinical users,” said Dalsin.

 

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

Imbed Biosciences Secures ISO 13485:2003 Certification

IMBED BIOSCIENCES SECURES ISO 13485:2003 CERTIFICATION

 

Madison, WI, September 9, 2016 – Imbed Biosciences, a developer of advanced biomaterials and wound care devices, announced today that the company has received certification from British Standards Institution (BSI) Group America, Inc. that the company complies with the requirements of ISO 13485:2003 for an integrated Quality Management System across all functions of the business, from design and development to manufacturing and supply. The scope of the certificate includes the design, manufacture, and distribution of sterile wound dressings with medicinal substances.

“This is a crucially important step in bringing our first antimicrobial wound dressing product, MicroLyte AG, to global marketplace,” said Imbed’s President and CEO Ankit Agarwal.  “Furthermore, I am very pleased that our small team has been able to achieve this certification in a relatively short period of time in a very capital efficient manner.  ISO 13485 certification provides an important level of assurance to our customers and partners that Imbed can reliably provide high quality products.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow facebook.com/imbedbio and @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

pdf-icon1

 

Imbed Receives FDA Clearance for Bacteria-Killing Wound Dressing

Imbed Receives FDA Clearance for Bacteria-Killing Wound Dressing

MADISON, WI (Aug 5, 2016) – Imbed Biosciences announced today that it has received clearance from the Food and Drug Administration (FDA) to market its patented Microfilm™ wound dressing—Microlyte® Ag, for human use. The dressing is an ultrathin hydrogel sheet as thin as human hair that is able to intimately conform to the contours of an underlying wound-bed. FDA has cleared Microlyte® Ag for management of hard to heal wounds under prescription use, and for small cuts and burns under over-the-counter use.

Like many dressings used today to treat burns and chronic wounds, Microlyte® Ag contains ionic and metallic silver to kill bacteria, but in much smaller quantities.

Photo: Open sore on dog

This chronic pressure sore on an Irish wolfhound received conventional treatment for more than three months at the UW–Madison School of Veterinary Medicine.

Photo: Dog's wound healing

Fourteen days after application of Microlyte, the sore is closed and well on its way to healing.

“Silver is an excellent antimicrobial agent,” said Ankit Agarwal, PhD, co-founder and CEO of the company, “as it is active against a broad range of bacteria and yeast. But the loadings of silver found in conventional silver dressings can be toxic to skin cells involved in wound healing”. Microlyte® Ag dressing contains as little as 1% of the silver found in other dressings in the clinics today, and is still effective in killing more than 99.99 percent of bacteria that it contacts, including some of the nastiest hospital-acquired superbugs such as methicillin-resistant staph aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

Microlyte® Ag overcomes a key problem with existing dressings — stiffness. A wound has bumps and fissures that are hiding places for bacteria. The dressing inherently adheres to moist wound surfaces and is so thin and flexible that it conforms into the fissures, leading to the sweet combination of greater destruction of bacteria at much lower doses of silver.

 

Microlyte® Ag has several other advantages. It retains moisture yet is ultra-thin and breathable to maintain a moist wound healing environment. The slow release of silver means the dressing can remain in place to provide antimicrobial effect for several days. And because the material is a hydrogel (a water-based gel), it can simply be rinsed off as needed before replacement. Experience with animals shows that the ultra-thin dressing simply sloughs off as the wound heals, so it has to be only reapplied, not painfully removed from a wound. All of these advantages should reduce the need to change dressings, which can be painful enough to require sedation, especially in children.

“Reducing or eliminating dressing changes reduces the pain that the patient experiences,” says co-founder Michael Schurr, MD, chair of general surgery at the Mountain Area Health Education Center in Asheville, North Carolina. “It also reduces costs in supplies and reduces the burden to the health care system that supplies visiting nurses to do the dressing changes.”

Photo: Microlyte being injected into a pig

Imbed’s Microlyte dressing is applied to a wound on a pig. The ultra-thin dressing conforms to the wound, bringing the antimicrobial silver into direct contact with bacteria.

“We are seeing in a limited number of cases that it does provide us with a remarkable new tool for dealing with chronic wounds” in dogs and cats treated at the University of Wisconsin-Madison School of Veterinary Medicine, says Prof. Jonathan McAnulty, DVM, PhD, chair of Surgical Sciences. “We certainly have no reason to think that this will be different with humans,” add McAnulty, who is also a company co-founder. “The principles are same, and a lot of the problems are the same.”

The dramatic closure of wounds that have resisted months of conventional treatment, “suggests that chronic bacterial contamination of the wound surface, even when it looks relatively healthy, is a significant factor inhibiting healing in many cases,” McAnulty says. “Once we treat with Microlyte® Ag dressing, we start to see very dramatic closure of these wounds.” McAnulty says he’s starting to use Microlyte® earlier in treatment. “Certainly it seems appropriate for prevention of infection as well as management.”

The dressing will compete in North America in the $2-billion market sector of “advanced wound dressings,” which are used to treat diabetic ulcers, venous ulcers, burns, bedsores and other difficult wounds. “We are doing a limited release of Microlyte® Ag dressing in certain U.S. hospitals to study impact on different wound types”, said Agarwal. The company plans to reach the market through licensing agreements with hospital suppliers and is discussing commercial-scale production of Microlyte® Ag dressings.

“We are excited to support the launch of this new advanced wound care dressing that can help heal painful wounds in millions of patients in U.S.”, said David Guinther, a partner in the venture capital group– WISC partners. “We will continue to support executive team in recruiting global distribution partners and product line expansion”.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow @Imbedbio on twitter.

About WISC Partners

Our mission at WISC Partners is to create wealth by helping a portfolio of well-chosen entrepreneurs in Wisconsin to build great companies that solve important customer problems. We accomplish this by injecting Strategic Operating Capital into these investments, which couples funding with company building experience, product and market expertise, corporate and business development networks, and highly engaged executive support. We are comprised of University of Wisconsin alumni, with offices in Madison, WI. For more information, please visit www.wiscpartners.com.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc. ankit@imbedbio.com

Source UW Madison: http://news.wisc.edu/uw-madison-spinoff-gets-fda-ok-for-bacteria-killing-wound-dressing/

 

Imbed Bio Wins 2016 Wound Care Innovation Award in Bremen, Germany

04-banner_EWMA2016-www_01

 

Imbed Bio Wins 2016 Wound Care Innovation Award in Bremen, Germany

Bremen, Germany (May 12, 2016) – Imbed Biosciences announces that its microfilm wound dressing technology has today won the annual 2016 Wound Care Innovation Award at the European Wound Management Association (EWMA) conference in Bremen, Germany. About 6,000 medical professionals attended the conference, which is the largest such annual gathering in Europe. In total, more than 1000 scientific presentations took place during the three-day conference. More than 180 companies exhibited their newest products.

Imbed was one of the five finalists invited to present at the Wound Care Innovation Symposium for the grand prize, sponsored by CMC Consulting Group, EWMA and Lohmann & Rauscher. Each company made a 10 minutes presentation of their technological innovations before an esteemed panel of judges from the industry. The other finalist companies were Kerecis Ltd (Iceland), Birken AG (Germany), Inotec AMD Ltd (UK), and NuTech Medical (AL, USA).

Imbed presented its microfilm wound dressing technology platform, which is a transparent, thin, synthetic hydrogel film with a coating of ionic and metallic silver. When placed on a moist wound, microfilm dressing absorbs wound moisture and forms a conforming gel sheet that can provide antimicrobial barrier to infections for several days. Microfilm dressings contain 100 times less silver than competitor silver-based wound dressings in clinics, allowing them to be used on day one of any wound management plan without fear of silver staining or toxicity. The product is currently under review for regulatory clearance for human use.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI. Imbed’s vision is to develop next-generation medical devices that can reduce patient pain and costs for management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its synthetic and biodegradable thin films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and promote wound healing. For more information, please visit www.imbedbio.com.

CONTACT INFORMATION
Ankit Agarwal, CEO
Imbed Biosciences Inc.
ankit@imbedbio.com

 

NIH to Showcase Imbed Bio in Innovation Zone at BIO 2016 in San Francisco, CA

BIO-2016-large

NIH to Showcase Imbed Bio in Innovation Zone at BIO 2016 in San Francisco, CA

Madison, WI (May 1, 2016)- Imbed Bio announces that it will exhibit at the 2016 Biotechnology Industry Organization (BIO) International Convention in San Francisco, CA from June 6-9, 2016. National Institutes of Health has selected to showcase Imbed Bio as one of its 50 top funded technologies. Imbed will host a kiosk in the Innovation Zone, an area of the exhibition floor that is dedicated to showcasing Small Business Innovation Research (SBIR) grantees.

SBIR grants provide early-stage funding for small businesses, and Imbed Bio currently has a $1.5M SBIR grant from the NIH to develop antimicrobial microfilm dressing with ionic and metallic silver for management of chronic wounds. Ankit Agarwal, PhD (CEO) will attend the convention and introduce company’s technology platform and pipeline products to potential customers, corporate partners and investors. Please contact Ankit Agarwal through the One-on-One Partnering System at the BIO Conference website if you would like to schedule a meeting at BIO 2016.

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI. Imbed’s vision is to develop next-generation medical devices that can reduce patient pain and costs for management of burns, chronic wounds, hernia meshes, gastro-intestinal defects, and dural membranes. Company has a portfolio of products in development based on its synthetic and biodegradable thin films platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and promote wound healing. For more information, please visit www.imbedbio.com.

CONTACT INFORMATION
Ankit Agarwal, CEO, Imbed Biosciences Inc.
ankit@imbedbio.com

Dow Chemist Joins Imbed Biosciences Team

Dow Chemist Joins Imbed Biosciences Team

Madison, WI, (December 1, 2014) – Imbed Biosciences, a developer of advanced biomaterials for surgical and wound care, announced today that Gaurav Pranami, Ph.D. will join the Imbed Biosciences team as Director of Research & Development.  Dr. Pranami will head expansion of Imbed’s bioactive polymeric microfilm technology and its transfer into scalable manufacturing processes. He brings 11 years of chemical and computational research experience to Imbed. He worked as senior engineer at Dow Chemical Company for the past 5 years on innovative inks, functional paper coatings, adhesives, textiles and non-wovens. Gaurav received his BS from the Indian Institute of Technology, Delhi, and his Ph.D. in Chemical Engineering from Iowa State University, Ames, IA, and did his post-doctoral research at University of Wisconsin-Madison.

“I have known Gaurav for several years and I am delighted that he is joining Imbed to lead research and development of microfilm technology,” said Ankit Agarwal, President and CEO of Imbed.  “His prior experience will help accelerate Imbed’s technical progress toward bringing our microfilm wound contact film dressings to market.”

“I have been closely monitoring Imbed’s progress for the past few years. I am excited for this opportunity to join the team and help bring the company’s exciting wound care technology to market,” said Pranami.

About Imbed Biosciences, Inc.

Imbed Biosciences is a privately held medical device company developing next-generation medical devices for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. Company has a portfolio of products in development based on its patented polymeric Microfilm™ platform that present bioactive molecules on tissue surfaces to manage wound infections, biofilms, and local pain and support wound healing. Imbed is backed by venture capital group WISC Partners based in Madison, WI. Company has also received research grants from National Institutes of Health and National Science Foundation. For more information, visit www.imbedbio.com and follow @imbedbio on twitter.

CONTACT INFORMATION

Ankit Agarwal, CEO, Imbed Biosciences Inc.

ankit@imbedbio.com

 

 

 

WISC Partners Makes Lead Investment in Imbed Biosciences

VentureBeat

WISC Partners Makes Lead Investment in Imbed Biosciences

 Madison, Wisconsin (September 11, 2014)  –  Strategic operating capital fund, Wisconsin Investment and Strategic Capital Partners (“WISC Partners”), has made the lead investment in Imbed Biosciences (“IMBED”) in order to advance the development and commercialization of their promising wound healing technology.

WISC Partners LP is a strategic operating capital fund that invests not just capital, but also provides expertise in company building, in business development, and in delivering liquidity events to its selected ventures. Comprised of University of Wisconsin alumni who have built their careers in Silicon Valley, the firm is committed to building wealth for both investors and entrepreneurs in the state of Wisconsin.

“We achieved everything we set out to do in our fund raising process and more”, says Ankit Agarwal, CEO and cofounder of IMBED. “WISC Partners has helped us to identify and now pursue additional applications and opportunities for our wound healing technology. We have already gained far more value than funding alone from our work together. This is a tremendous partnership for us.”

In addition to the investment by WISC Partners, IMBED has also been recently awarded with $1.5 million in funding from the National Institute of Health to further the testing of its unique polymeric nanofilm technology, which is designed for wound healing and surgical applications.

According to David Guinther, a General Partner at WISC Partners, “IMBED has everything that we look for in an investment: a strong team of founders, impressive progress to date, a clear product-market fit, and a product with the potential to become a platform with broad applications. We are very pleased to be working with the remarkable team at IMBED.”

Adds Sanjeev Chitre, also a General Partner at WISC Partners and who is joining the Board of Directors of IMBED, “This technology has the potential to address a wide range of challenges in advanced wound care, and we see additional opportunities within the military, in the veterinarian market, and in international markets. The identification and effective pursuit of these opportunities is part of the value that WISC Partners brings to IMBED.”

 

About WISC Partners

Our mission at WISC Partners is to create wealth by helping a portfolio of well-chosen entrepreneurs in Wisconsin to build great companies that solve important customer problems. We accomplish this by injecting Strategic Operating Capital into these investments, which couples funding with company building experience, product and market expertise, corporate and business development networks, and highly engaged executive support. We are comprised of University of Wisconsin alumni, with offices in Madison, WI and Milpitas, CA.For more information, please visit www.wiscpartners.com.

 

About Imbed Biosciences Inc.

Imbed Biosciences is a privately held medical device company, located in Madison, WI, that develops advanced materials for wound healing and surgical applications. It has developed polymeric nanofilms and microfilms for delivering tailored loadings of bioactive molecules on tissue surfaces. Its vision is to develop next-generation surgical devices that can reduce patient pain and overall treatment costs, including antimicrobial dressings for dermal wounds, hernia surgical meshes, barrier films for gastro-intestinal defects, and dural membranes. The company’s first family of products targets the antimicrobial wound dressings market. For more information, please visit www.imbedbio.com.

 

CONTACT INFORMATION

David Guinther, General Partner, WISC Partners
david@wiscpartners.com

 

Ankit Agarwal, CEO, Imbed Biosciences Inc.
ankit@imbedbio.com
Phone: 515-708-1330

 

NIH Awards Imbed Bio a $1.5M Grant to Develop Advanced Wound Healing Nanofilm

VentureBeat

NIH Awards Imbed Bio a $1.5M Grant to Develop Advanced Wound Healing Nanofilm

Madison, WI (July 28, 2014)– Imbed Biosciences, Inc, a medical device company developing advanced materials for wound healing and surgical applications, announced today that it has been awarded a $1.5M competitive Small Business Innovation Research (SBIR) Phase II grant from National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of National Institutes of Health (NIH).

Ankit Agarwal, PhD, Founder/CEO of Imbed and the Principal Investigator on the grant, said, “this award supports our ongoing investment to develop unique polymeric nanofilm dressings containing silver nanoparticles. The dressing would allow closure of hard-to-heal burns and chronic wounds without infection or silver toxicity”. In Phase I, company validated the feasibility of employing these ultrathin conformal wound dressings in contaminated wounds in mice, which expedited wound closure by reducing bacterial colonization.

“It a very competitive award, which validates the uniqueness of this polymeric nanofilm technology. A significant merit is that the concept is adaptable to delivery of a wide range of bioactive molecules on tissue surfaces, providing a broadly applicable healthcare materials platform”, said co-founder Nicholas Abbott, PhD, Professor in Department of Chemical and Biological Engineering at University of Wisconsin-Madison.

“This next-generation wound dressing will be applicable at the onset of any wound treatment plan without silver toxicity. The nanofilm dressing dissolves in wound over time, potentially reducing painful dressing changes”, said co-founder Prof. Michael Schurr, MD, burn and trauma surgeon in School of Medicine at University of Colorado, Denver.

With this funding, Imbed plans to begin testing the nanofilm dressing in pigs. “Clinical data from porcine wounds will be used to obtain regulatory clearance for human clinical trials”, said co-founder Prof. Jonathan McAnulty, DVM, PhD, leading porcine studies as a part of this grant in School of Veterinary Medicine at University of Wisconsin-Madison.

“Wound healing research is an important component of the NIAMS portfolio. It is part of an effort to reduce the impact of human skin wounds on public health and the economy. This SBIR Phase II award to Imbed Bio reflects our commitment to meet this public need,” said Dr. Hung Tseng, Program Director of the Skin Repair, Regeneration and Pigmentation Program in the Division of Skin and Rheumatic Diseases at the NIAMS.

“We have a team of renowned experts in surface engineering, microbiology and surgical sciences committed to bring this wound healing nanofilm technology into clinics”, said Agarwal.

 

About Imbed Biosciences:

Imbed Biosciences Inc. is a privately held medical device company located in Madison, WI. Company has patent-pending technologies on polymeric nanofilms and microfilms for delivering tailored loadings of bioactive molecules on tissue surfaces. Company’s vision is to develop next-generation surgical devices that can reduce patient pain and overall treatment costs, including antimicrobial dressings for dermal wounds, hernia surgical meshes, barrier films for gastro-intestinal defects, and dural membranes. For more information, visit http://www.imbedbio.com.

Contact Information:

Ankit Agarwal, CEO

ankit@imbedbio.com